IONS
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It's been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That's likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of the American...Today should be a big day for biotech
JPMorgan Chase holds its big biotech conference today, Monday January 9, and last week’s momentum in the sector as well as likely upbeat guidance to begin the conference at 10:30 a.m. Eastern time from Celgene (CELG) should have the sector on the move.
Notes You Need for December 21 updated 11:30 p.m.: Natural gas, CHK, IONS, oil pipelines, DRAM market
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Clinical trial delivers good news for all of pipeline at Ionis, upping target price
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Jim’s Stock Alerts
Download Jim’s eBook for Free
